ACA
QNCX icon

Atlas Capital Advisors’s Quince Therapeutics QNCX Stock Holding History

Atlas Capital Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15
Closed -$275K – 952
2021
Q3 		$275K Hold
15
– – 0.04% 300
2021
Q2 		$159K Hold
15
– – 0.03% 386
2021
Q1 		$108K Buy
+15
New +$108K 0.02% 407
2020
Q3 		– Sell
-15
Closed -$139K – 522
2020
Q2 		$139K Hold
15
– – 0.03% 357
2020
Q1 		$137K Hold
15
– – 0.04% 326
2019
Q4 		$168K Buy
15
+7
+88% +$42.2K 0.04% 336
2019
Q3 		$37.4K Hold
8
– – 0.01% 484
2019
Q2 		$63.8K Buy
+8
New +$47.8K 0.02% 453

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Atlas Capital Advisors's QNCX Position: Q4 2021 in Review

Atlas Capital Advisors sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 15 shares — an estimated $275K sold.

Atlas Capital Advisors first reported a position in QNCX in Q2 2019 and held it in 8 quarters. The position peaked at $275K in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

  • Atlas Capital Advisors reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Atlas Capital Advisors sold 15 Quince Therapeutics shares in Q4 2021, an estimated $275K.
  • Atlas Capital Advisors first reported a position in Quince Therapeutics in Q2 2019 and held it in 8 quarters.
  • Atlas Capital Advisors's Quince Therapeutics position peaked at $275K in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Atlas Capital Advisors's 13F filing for Q4 2021, filed 1 Feb 2022.